$10.63 + 0.57 (+5.666%)

3 month stock price graph

4:00 PM ET on Feb 16, 2018 Pricing delayed 20 minutes

Investors & Media

Investors & Media

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

Dicerna Corporate Fact Sheet


Dicerna's President and CEO Doug Fambrough provides an update on the company and its GalXC™ platform in an interview with Small Cap Nation

To watch the full initial interview, click here.